Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial

Simple item page
dc.contributor.authorBerk, M.
dc.contributor.authorAgustini, B.
dc.contributor.authorWoods, R.L.
dc.contributor.authorNelson, M.R.
dc.contributor.authorShah, R.C.
dc.contributor.authorReid, C.M.
dc.contributor.authorStorey, E.
dc.contributor.authorFitzgerald, S.M.
dc.contributor.authorLockery, J.E.
dc.contributor.authorWolfe, R.
dc.contributor.authorMohebbi, M.
dc.contributor.authorDodd, S.
dc.contributor.authorMurray, A.M.
dc.contributor.authorStocks, N.
dc.contributor.authorFitzgerald, P.B.
dc.contributor.authorMazza, C.
dc.contributor.authorMcNeil, J.J.
dc.date.issued2021
dc.descriptionPublished online: 27 January 2021
dc.description.abstractLate-life depression is common and often inadequately managed using existing therapies. Depression is also associated with increased markers of inflammation, suggesting a potential role for anti-inflammatory agents. ASPREE-D is a sub-study of ASPREE, a large multi-centre, population-based, double-blind, placebo-controlled trial of aspirin vs placebo in older Australian and American adults (median follow-up: 4.7 years) of whom 1879 were depressed at baseline. Participants were given 100 mg daily dose of aspirin or placebo. Depressive symptoms were assessed annually using the validated, self-rated short version of the Center for Epidemiological Studies Depression scale. There was a significant increase in depressive scores (0.6; 95% CI 0.2 to 0.9; χ2 (1)=10.37; p=0.001) and a decreased score in the mental health component of a quality of life scale (–0.7; 95% CI –1.4 to –0.1; χ2 (1)=4.74; p=0.029) in the aspirin group compared to the placebo group. These effects were greater in the first year of follow-up and persisted throughout the study, albeit with small to very small effect sizes. This study failed to demonstrate any benefit of aspirin in the long-term course of depression in this community-dwelling sample of older adults over a 5-year period, and identified an adverse effect of aspirin in the course of depression in those with pre-existing depressive symptoms.
dc.description.statementofresponsibilityMichael Berk, Bruno Agustini, Robyn L. Woods, Mark R. Nelson, Raj C. Shah, Christopher M. Reid ... et al.
dc.identifier.citationMolecular Psychiatry, 2021; 26(9):5161-5170
dc.identifier.doi10.1038/s41380-021-01020-5
dc.identifier.issn1359-4184
dc.identifier.issn1476-5578
dc.identifier.orcidStocks, N. [0000-0002-9018-0361]
dc.identifier.urihttp://hdl.handle.net/2440/130043
dc.language.isoen
dc.publisherSpringer
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1127060
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1081901
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/334047
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1059660
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1156072
dc.rights© The Author(s), under exclusive licence to Springer Nature Limited 2021.
dc.source.urihttps://doi.org/10.1038/s41380-021-01020-5
dc.subjectHumans
dc.subjectAspirin
dc.subjectDouble-Blind Method
dc.subjectDepression
dc.subjectQuality of Life
dc.subjectAged
dc.subjectAustralia
dc.titleEffects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

General Practice publications